CiMaas is a start-up biotech company focused on the development of immune cell therapy for cancer patients. The company's lead products are a dendritic cell vaccine that is ready to be validated and tested in clinical trials and natural killer (NK) cells obtained from healthy donors that have already proven in rodent studies to demonstrate great anti-tumor activity.